Tokyo, Japan

Yusuke Ota

USPTO Granted Patents = 17 

 

 

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Kanagawa, JP (2012 - 2015)
  • Tokyo, JP (2011 - 2023)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):

Title: Yusuke Ota: Innovator in Antibody-Drug Conjugates

Introduction

Yusuke Ota is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 17 patents to his name, Ota's work is at the forefront of medical innovation.

Latest Patents

Ota's latest patents include groundbreaking methods for treating tumors through the administration of claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugates. These inventions provide novel approaches to cancer treatment by utilizing unique antibody-pyrrolodiazepine derivatives. Additionally, he has developed antibody-drug conjugates that comprise substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines, which are useful in various therapeutic applications.

Career Highlights

Throughout his career, Yusuke Ota has worked with notable companies such as Arqule, Inc. and Renesas Electronics Corporation. His experience in these organizations has allowed him to refine his expertise in the development of innovative medical solutions.

Collaborations

Ota has collaborated with esteemed colleagues, including Jean-Marc Lapierre and Sudharshan Eathiraj. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Yusuke Ota's contributions to the field of biotechnology and his innovative patents position him as a key figure in medical research. His work continues to pave the way for new treatments and therapies that can significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…